Thomas J. DesRosier
Net Worth

Last updated:

What is Thomas J. DesRosier net worth?

The estimated net worth of Mr. Thomas J. DesRosier is at least $7,318,299 as of 18 Nov 2024. He owns shares worth $2,196,870 as insider, has earned $84,579 from insider trading and has received compensation worth at least $5,036,850 in Seres Therapeutics, Inc..

What is the salary of Thomas J. DesRosier?

Mr. Thomas J. DesRosier salary is $719,550 per year as Chief Legal Officer, Executive Vice President & Sec. in Seres Therapeutics, Inc..

How old is Thomas J. DesRosier?

Mr. Thomas J. DesRosier is 70 years old, born in 1955.

What stocks does Thomas J. DesRosier currently own?

As insider, Mr. Thomas J. DesRosier owns shares in one company:

Company Title Shares Price per share Total value
Seres Therapeutics, Inc. (MCRB) Chief Legal Officer, Executive Vice President & Sec. 135,192 $16.25 $2,196,870

What does Seres Therapeutics, Inc. do?

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MCRB logo
MCRB
Seres Therapeutics, Inc.
$16.25

Thomas J. DesRosier insider trading

Seres Therapeutics, Inc.

Mr. Thomas J. DesRosier has made 8 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently he sold 878 units of MCRB stock worth $475 on 18 Nov 2024.

The largest trade he's ever made was exercising 25,000 units of MCRB stock on 26 Jan 2020. As of 18 Nov 2024 he still owns at least 135,192 units of MCRB stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 878 $0.54 $475
Option
Restricted Stock Units 2,656 N/A N/A
Option
Common Stock 2,656 N/A N/A
Sale
Common Stock 4,259 $0.69 $2,939
Option
Restricted Stock Units 13,500 N/A N/A
Option
Common Stock 13,500 N/A N/A
Sale
Common Stock 873 $0.84 $733
Option
Restricted Stock Units 2,656 N/A N/A
Option
Common Stock 2,656 N/A N/A
Option
Common Stock 2,656 N/A N/A
Option
Restricted Stock Units 2,656 N/A N/A
Sale
Common Stock 843 $0.94 $792
Sale
Common Stock 3,939 $1.08 $4,254
Option
Common Stock 10,625 N/A N/A
Option
Restricted Stock Units 10,625 N/A N/A
Sale
Common Stock 4,156 $1.35 $5,611
Option
Common Stock 13,501 N/A N/A
Option
Restricted Stock Units 13,501 N/A N/A
Option
RESTRICTED STOCK UNITS 25,000 N/A N/A
Option
COMMON STOCK 25,000 N/A N/A
Sale
COMMON STOCK 5,471 $5.75 $31,480
Option
COMMON STOCK 15,000 N/A N/A
Option
RESTRICTED STOCK UNITS 15,000 N/A N/A
Option
RESTRICTED STOCK UNITS 10,000 $10.42 $104,200
Option
COMMON STOCK 10,000 $10.42 $104,200
Sale
COMMON STOCK 3,475 $11.02 $38,295

Seres Therapeutics key executives

Seres Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. David S. Ege Ph.D. (51) Executive Vice President & Chief Technology Officer
  • Mr. Eric D. Shaff M.B.A. (49) Pres, Chief Executive Officer & Director
  • Mr. Thomas J. DesRosier (70) Chief Legal Officer, Executive Vice President & Sec.